Objective: Cardiac hypertrophy is a compensatory response to increased mechanical load. Since Fas receptor activation is an important component in hypertrophy induced by pressure-and volume-overload, deciphering the underlying signaling pathways is of prime importance. Based on our previous work showing that in mice and rats ventricular myocytes the electrophysiological disturbances and diastolic [Ca 2+ ] i -rise caused by 3 h of Fas activation are dependent on the Fas Y phospholipase C (PLC) Y 1,4,5-inositol trisphosphate (1,4,5-IP 3 ) Y sarcoplasmic reticulum (SR) [Ca 2+ ] i release pathway, we tested the hypothesis that this pathway is also critical for Fasmediated hypertrophy. Methods: The effects of 24 h Fas activation in cultured neonatal rat ventricular myocytes (NRVM) were analyzed by means of RT-PCR, Western blot, immunofluorescence and fura-2 fluorescence. Results: Fas activation increased nuclei surface area, atrial natriuretic peptide and connexin43 (Cx43) mRNA, the protein levels of total Cx43 and non-phosphorylated Cx43, and sarcomeric actin, all indicating hypertrophy. Concomitantly, Fas activation decreased mRNA of SERCA2a, the ryanodine receptor (RyR) and nuclear IP 3 R3. Further, Fas activation caused NFAT nuclear translocation. The hypertrophy was abolished by U73122, xestospongin C (blockers of the 1,4,5-IP 3 pathway), genistein and by the PI3K blocker LY294002. Conclusions: Fas-mediated hypertrophy is dependent on the 1,4,5-IP 3 pathway, which is functionally inter-connected to the PI3K/AKT/ GSK3h pathway. Both pathways act in concert to cause NFAT nuclear translocation and subsequent hypertrophy.
Introduction
Recent studies have shown that activation of the cardiac Fas receptor (Fas) causes both apoptotic and non-apoptotic deleterious effects [1] [2] [3] [4] . In contrast to many Fas-baring cell lines and tissues, Fas activation in ventricular myocytes does not cause apoptosis, indicating that Fas expression per se does not necessarily commit cells to apoptosis. Specifically, we and others have demonstrated that whereas normoxic myocytes are resistant to apoptosis induced by Fas activation, hypoxia predisposes myocytes to Fasmediated apoptosis [1, 3, 4] . In a series of studies we found that in adult murine and neonatal rat ventricular myocytes (NRVM), 3 h of Fas activation caused a wide range of functional disturbances, including action potential changes, early-and delayed after depolarizations, arrhythmias, intracellular Ca 2+ ([Ca 2+ ] i ) rise, decreased I to and increased I Ca,L [5, 6] . Our key finding was that these effects were exclusively dependent on the Fas Y phospholipase C (PLC) Y 1,4,5-IP 3 Y SR [Ca 2+ ] i release pathway and on tyrosine kinases (TK) phosphorylation [5, 6] . In brief, we showed that: (1) the above mentioned effects were blocked by the PLC inhibitor U73122 and by xestospongin C, a specific blocker of the SR 1,4,5-IP 3 -operated Ca 2+ channels, and were reproduced by intracellular application of 1,4,5-IP 3 ; (2) Fas activation increased 1,4,5-IP 3 levels.
Recently, Dimmeler's group has shown that 4 h of Fas activation in NRVM caused hypertrophy, and that lpr mice lacking functional Fas demonstrated rapid-onset of left ventricular dilatation and failure, absence of compensatory hypertrophy and increased mortality [1] , indicating that the hypertrophy was Fas-dependent. Because of the key role of hypertrophy in major heart diseases, and based on our previous studies, we tested the hypothesis that the 1,4,5-IP 3 pathway is critical for Fas-mediated hypertrophy. This work shows for the first time the involvement of the ubiquitous 1,4,5-IP 3 pathway in ventricular hypertrophy, suggesting that modulators of this pathway specifically targeted to cardiac muscle may have an important therapeutic value.
Methods

Cultures preparation, Fas activation, apoptosis determination and [Ca 2+ ] i transients measurement
NRVM cultures were prepared from ventricles of 1-2-day-old Sprague -Dawley rats [4] , and experiments performed on cultures 4 -6 days after plating. The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . To inhibit non-cardiac muscle growth, BrdU was included in the culture medium. Fas was activated by recombinant Fas ligand (rFasL) (10 ng/mL) and an enhancing antibody (1 Ag/mL) (Alexis, San Diego, CA, USA). This concentration was chosen based on a study [1] showing that in the concentration range of 1 -100 ng/ml, maximal hypertrophy (indicated by [ 3 H] leucine incorporation) was attained at 10 ng/mL. For each protocol apoptosis was measured by the DAPI assay [4] , in two wells (500 myocytes measured in each well), prepared from 3 different litters, altogether counting 3000 myocytes. [Ca 2+ ] i transients were measured by means of fura-2 fluorescence from cultures maintained at 37 -C and stimulated at 0.5 Hz [4] .
Immunoblotting
NRVM were harvested in lysis buffer, and 40 Ag of total protein were separated by 12% SDS-PAGE gels, transferred to nitrocellulose membranes, and immunoblotted [4] . The primary antibodies were anti-Cx43 (Chemicon International, Temecula, CA, USA) and anti-nonphosphorylated (NP) Cx43 antibody (Zymed Laboratories, San Francisco, CA, USA). Immune complexes were detected using the Enhanced Chemiluminescence detection system (Perkin Elmer Life Sciences, Boston, MA, USA) [7] .
Immunofluorescence staining
Actin measurements: NRVM were stained with Alexa Phalloidin (Alexis, Cornerstone Court, San Diego, CA, USA). Actin was quantified by measuring the fluorescence intensity using custom-made ''Open View'' software, from 12 different areas in each slide, from 4 experiments. Nuclei were visualized by DAPI (Vector Laboratories, Inc., Burlingame, CA, USA). NFAT translocation: NRVM were stained using indirect immunofluorescence staining with polyclonal anti-NFAT (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA), monoclonal anti-a-actinin (Sigma, St. Louis, MO, USA) antibodies, and anti mouse-FIT-C + anti-rabbit rhodamin (Jackson ImmunoResearch Laboratories, Inc., Baltimore, PA, USA). Nuclei were visualized by Topro stain (Jackson ImmunoResearch Laboratories). The slides were visualized using a Provis AX70 fluorescence microscope at Â 40 magnification (Olympus, Tokyo, Japan). 
RT-PCR assay
Total RNA was isolated using EZ-RNAi kit (Biological Industries, Beit-Haemek, Israel) and Reverse Transcriptase (RT) reaction was conducted [8] . The nucleotides used and the cycling conditions are presented in Table 1 . All PCR products were given a final elongation stage at 72 -C for 10 min. Products were resolved on 1.5% agarose gel. 
Nuclear measurements
For nuclear staining, slides were stained with hematoxylin and eosin. Morphometric determination of myocytes nuclear dimensions was performed using image analysis software (analySIS docu\3.0, Soft Imaging System, Munster, Germany). The system consists of an Olympus CH-40 bright field microscope (Â 100 objective) fitted with a CCD camera. The peripheries of selected nuclei were traced with the mouse cursor and the values (in Am 2 )
were determined. Special care was taken to ensure that the areas selected for analysis on the slides were comparable between the treated and control samples. Altogether, 60 nuclei were measured from two different litters for each group.
Chemicals
Unless otherwise indicated, chemicals were purchased from Sigma (Sigma Chemical Co, St. Louis, MO, USA).
Cx43/Actin Values were normalized to control cultures, which were set as 1.0. *P < 0.05.
Statistical analysis
Results were expressed as mean T SEM. Means of two populations were compared using Student's t-test for unpaired observations. A value of P < 0.05 was considered significantly different.
Results
Fas-induced hypertrophy
Firstly, we confirmed that Fas activation in NRVM does not cause apoptosis, although the apoptotic machinery is responsive, as evidenced by the ability of H 2 O 2 to cause apoptosis (Fig. 1A) . Next, we characterized the time course (3, 6 and 24 h) of the hypertrophy induced by Fas activation. As shown in Fig. 1C , rFasL increased ANP mRNA in a time-dependent fashion, to the extent comparable to that caused by endothelin-1 (ET-1). Cx43 mRNA levels (known to be affected by hypertrophic stimuli [9 -11] ) were also increased by rFasL in a time-dependent fashion, reaching a 2-fold change at 24 h (Fig. 1D ). Since both ANP and Cx43 mRNA levels peaked at 24 h, subsequent experiments were performed at this time point. In agreement with the Cx43 mRNA data (Fig. 1D) , total and non-phosphorylated (NP) Cx43 protein expression were increased at 24 h Fas activation (Fig. 2B -D) . Two additional markers of hypertrophy, nuclear area [12, 13] and sarcomeric actin were also augmented by Fas activation (Fig. 1B and E) . It is noteworthy that due to the pronounced overlap between myocytes in culture, accurate measurement of cell area in confluent NRVM cultures is practically impossible.
The effect of Fas activation on [Ca 2+ ] i handling proteins
Following a previous study showing that hypertrophy caused by aortic stenosis [14] is associated with alterations in key components of the intracellular Ca 2+ handling Values were normalized to control cultures, which were set as 1.0. *P < 0.05. machinery, we tested whether similar changes occur in Fasmediated hypertrophy. Firstly, we tested the mRNA levels of sarco(endo)plasmic reticulum Ca 2+ -ATPase (SERCA), responsible for pumping Ca 2+ back into the SR. Of the three cardiac SERCA isoforms, SERCA2a, SERCA2b, and SERCA3, the first is the major isoform in cardiomyocytes. As depicted in Fig. 3A , Fas activation decreased SERCA2a mRNA level by 24%. Next, we tested the effect of Fas activation on the cardiac ryanodine receptor (RyR) SR isoform-RyR2, which is central to the Ca 2+ -induced release of Ca 2+ (CIRC) machinery. As shown in Fig. 3B , RyR2 was decreased by Fas activation to a similar extent as SERCA2a (¨20%). Finally, we determined the effect of Fas activation on the intracellular IP 3 receptors (IP 3 R). Of the three known isoforms, we focused on the two that exist in neonatal and adult rat ventricular myocytes [15] . Whereas mRNA level of the type 2 cytosolic-localized IP 3 R [15] was unchanged by Fas activation (Fig. 3C) , that of the nuclear IP 3 R type 3 was decreased by 25% (Fig. 3D ).
The involvement of the 1,4,5-IP 3 pathway in Fasmediated hypertrophy
The first step in testing the 1,4,5-IP 3 hypothesis was to determine whether the specific PLC blocker U73122 [4] interferes with Fas-mediated hypertrophy. In support of the hypothesis, U73122 blocked rFasL-induced increase in actin fluorescence ( Fig. 2A) , as well as total and NP Cx43 protein (Fig. 2B -D) , and ANP and Cx43 mRNA (Fig. 4A -C) . Furthermore, blocking the SR 1,4,5-IP 3 -operated Ca 2+ release channel with xestospongin C [4] also prevented rFasL-mediated increase in ANP and Cx43 mRNA levels ( Fig. 4A -C) . In support of our notion that 1,4,5-IP 3 -mediated Ca 2+ release is the main source triggering the hypertrophic program, we found that the RyR blocker ryanodine (10 À 5 mmol/l) did not prevent rFasL-induced increase in ANP mRNA level (Fig. 4D) .
Since the only known function of the 1,4, (Fig. 5) . The effects of Fas activation were arrhythmias (as we previously reported [4] ) occurring throughout the test period, and time-dependent changes in diastolic [Ca 2+ ] i , firstly increasing and then decreasing towards control levels (Fig. 5 ). In agreement with our previous report (focusing on 3 h of Fas activation) [4] , the arrhythmias occurring at 24 h of Fas activation were also Values were normalized to control cultures, which were set as 1.0. *P < 0.05.
blocked by U73122 and genistein ( Fig. 5D and E) . The persistence of the arrhythmias and the increased ANP and Cx43 mRNA levels (Fig. 5F ) in the presence of a transient increase in diastolic [Ca 2+ ] i will be addressed in the Discussion.
Fas-mediated hypertrophy is blocked by tyrosine kinases inhibition
Because of the clinical significance of Fas-mediated hypertrophy, identifying drug-responsive elements in this pathway which can serve as potential targets for attenuating Fas-based myocardial dysfunction is of prime importance. Based on our recent study showing that the omnipotent tyrosine kinases (TK) inhibitor genistein prevented Fasmediated acute effects [6] , we tested whether inhibiting TK will also attenuate Fas-mediated hypertrophy. Indeed, genistein blocked the hypertrophy, as evidenced by lack of change in ANP and Cx43 mRNA (Fig. 4A -C) , and total Cx43 protein (Fig. 2B -C) . Concomitantly, genistein increased the NP-Cx43 level, which is probably due to its inhibitory effect of TK phosphorylation site(s) located on the Cx43 molecule [16] .
The effect of Fas activation on the nuclear factor of activated T cell (NFAT)
The NFAT family of transcription factors is dephosphorylated upon activation of the Ca 2+ /CaM-dependent phosphatase calcineurin, resulting in unmasking of their nuclear localization signals thereby permitting nuclear import [17] . The requirement for NFAT translocation in calcineurin-mediated hypertrophy was confirmed [18] , as well as the fact that cardiac hypertrophy is suppressed by activated glycogen synthase-3h (GSK3h) which is upstream to NFAT and causes its nuclear export [19] . Based on previous studies showing that hypertrophic signals such as endothelin-1 [18] cause NFAT nuclear translocation (and hypertrophy), we tested whether NFAT is involved in Fas-mediated hypertrophy. As seen in Fig. 6  (panel B, left side) , while in non-stimulated myocytes, NFATc1 (an isoform translocated by endothelin-1) displayed a predominant cytosolic localization (the stained nuclei are shown in the lower panel), Fas activation for 3 h caused intense NFATc1 nuclear translocation (panel B, right side), as evidenced by the Topro-stained nuclei (panel C, right side).
The interaction between the 1,4,5-IP 3 and PI3K/AKT pathways
Earlier studies have shown that activation of the hypertrophic program by Fas activation, and h-adrenergic and G q -coupled receptors leads to GSK3h inactivation, predominantly through the PI3K/Akt pathway [1,19 -22] . To test whether the 1,4,5-IP 3 and the PI3K/Akt pathways operate independently or in concert to cause Fas-mediated hypertrophy, we determined whether Fas activation can induce hypertrophy in the presence of LY294002, a PI3K/ Akt inhibitor. In agreement with Schlü ter et al. [23] , LY294002 blocked Fas-mediated hypertrophy, indicated by ANP mRNA level (Fig. 7A) . Importantly, LY294002 also prevented the development of Fas-mediated arrhythmias (Fig. 7B) , and the diastolic [Ca 2+ ] i rise commonly seen at 3 h Fas activation (4 different experiments, total of 20 myocytes measured). As will be discussed below, these findings suggest that the 1,4,5-IP 3 and the PI3K/Akt pathways are functionally inter-connected.
Discussion
In support of our working hypothesis that the Fas Y PLC Y 1,4,5-IP 3 Y SR [Ca 2+ ] i release pathway is responsible for Fas-mediated hypertrophy, we found that the hypertrophy was blocked by U73122 -a PLC inhibitor, and xestospongin C -a specific inhibitor of the 1,4,5-IP 3 -operated SR Ca 2+ release channels. Importantly, we found that the 1,4,5-IP 3 and the PI3K pathways are inter-connected, causing NFAT nuclear translocation.
The hypertrophy markers
Fas-mediated hypertrophy was associated with increased ANP mRNA, sarcomeric actin and nuclear area. At 24 h of Fas activation the first two markers increased by¨2-2.5-fold, resembling the effects of the hypertrophy inducers norepinephrine, and the renin-angiotensin system activation [24, 25] . Nuclear area was increased by 50%, similar to the effect seen in cardiac hypertrophy caused in rats by aortocaval fistula or pulmonary artery constriction [12, 13] . A novel effect of Fas activation is a marked increase in Cx43, the main gap junctional protein in ventricular myocytes [26] . At 24 h of Fas activation, Cx43 mRNA, total Cx43 and NP Cx43 increased by 80% (Fig. 1D) , 70% (Fig. 2C) and 130% (Fig. 2D) , respectively. These results resemble those reported by Saffitz's group who showed that in NRVM, angiotensin II and the membrane-permeant cAMP analogue db-cAMP (hypertrophy inducers) caused a 2 -4 fold increase in Cx43 protein expression, which resulted from increased synthesis [26] . Since in our study both Cx43 mRNA and protein were augmented, it is likely that Fas activation also increased Cx43 synthesis. These changes in Cx43 concomitant with the hypertrophy can contribute under pathophysiological conditions to development of anatomical and functional substrates of arrhythmias, frequently seen in the hypertrophic myocardium [28] . In addition to the changes in the hypertrophy markers, Fas activation decreased the expression of three key proteins associated with [Ca 2+ ] i handling: SERCA (24%, Fig. 3A ), RyR2 (Fig. 3B, 18% ) and IP 3 R type 3 (Fig. 3D, 25% ). In agreement with our findings, in cultures treated for 24 h with angiotensin II, SERCA and RyR were decreased by 50% and 45% respectively [29] . Similarly, in a volumeoverload model in rats, the decrease in SERCA mRNA was associated with a decrease in RyR mRNA and with a progressive left ventricular dysfunction [30] . Our IP 3 R findings differ from those of Go et al. who showed that in failing human hearts RyR mRNA decreased whereas IP 3 R mRNA increased [31] . While we did not determine how Fas activation affected RyR, SERCA and the IP 3 R, we propose that the combined decrease in these proteins may contribute to Fas-mediated cardiac dysfunction.
The involvement of the 1,4,5-IP 3 pathway in Fasinduced hypertrophy
Our working hypothesis that 1,4,5-IP 3 is a key participant in Fas-mediated hypertrophy is supported by the findings that both U73122 and xestospongin C prevented Fas-mediated hypertrophy. This is the first demonstration that the ubiquitous second messenger 1,4,5-IP 3 2+ release) leading to hypertrophy, we determined whether the well established calcineurin-mediated, NFAT nuclear translocation is involved in Fas-mediated hypertrophy. Indeed, as shown in Fig. 6 , Fas activation caused nuclear translocation of NFATc1. The NFAT proteins contain an N-terminal regulatory domain that controls their nuclear import in response to calcineurin activation [32] . While in nonstimulated cells this regulatory domain is phosphorylated and masks the nuclear localization sequence, causing NFAT proteins to be sequestered in the cytoplasm, calcineurin activation causes NFAT nuclear localization which is sufficient to induce cardiac hypertrophy [33] . Our findings are in close agreement with previous reports, such as that by Van Rooij et al., showing that endothelin-1 caused NFATc1 nuclear translocation and hypertrophy [18] .
In the present work we identified two serially-connected signaling elements involved in Fas-mediated hypertrophy: the 1,4,5-IP 3 and the NFAT; the issue which should be addressed is the link between the two pathways. According to our proposed model (Fig. 8) , the link is 1,4,5-IP 3 -mediated Ca 2+ release, which activates calcineurin, subsequently triggering NFAT nuclear translocation and the consequent hypertrophy [32] . In this regard, it is noteworthy that diastolic [Ca 2+ ] i peaked at 3 h of Fas activation, and then returned back to control levels at 24 h. At the same time, the extent of hypertrophy steadily increased during the 24 h period (Fig. 5) . This lack of complete association between diastolic [Ca 2+ ] i changes and the increase in the hypertrophic response does not necessarily negate the Fcalcium connection_ concept. Hence, we propose that the rise in diastolic [Ca 2+ ] i (at 3 h) activated various intracellular targets such as calcineurin (which triggered hypertrophy), and, although later on, diastolic [Ca 2+ ] i declined towards control levels, the hypertrophic response persisted and even gradually increased (compared to 3 h). This concept is supported by the occurrence of arrhythmias (which were blocked by U73122 and genistein, Fig. 5 ) at 24 h of Fas activation despite the decline of diastolic [Ca 2+ ] i to control levels. Therefore, we propose that 1,4,5-IP 3 -mediated Ca 2+ release is the trigger that initiates the hypertrophic program.
4.3.
The interaction between the 1,4,5-IP 3 and the PI3K/ AKT pathway An important finding was that both the 1,4,5-IP 3 pathway (U73122 and xestospongin C) and the PI3K/Akt pathway (LY294002) inhibitors completely blocked Fas-mediated hypertrophy, indicating that these pathways share a common link (Fig. 8) . These findings are in accord with a report showing that LY294002 blocked the increase in diastolic [Ca 2+ ] i and the accompanying arrhythmias in neonatal cardiac myocytes as well as [Ca 2+ ] i rise in human hepatoma-derived cell line HepG2 [34, 35] . According to our model (Fig. 8) , the first step in Fas-based hypertrophy is Fas engagement, which via TK phosphorylation leads to PI3K activation. This in turn results in PLC activation by PIP2 -a PI3K product, which anchors PLC to the cell membrane [34] , leading to increased 1,4,5-IP 3 production. Binding of 1,4,5-IP 3 to its SR receptors causes Ca 2+ release, a phenomenon demonstrated by us [4] and others [15, 36] . Subsequently, the [Ca 2+ ] i rise activates calcineurin which causes translocation to the nucleus of NFAT by its dephosphorylation, which is an essential step in the hypertrophic response [37, 38] . Concurrently, Fas-mediated PI3K activation leads to inactivation of GSK3h (by its phosphorylation) [1] , which is an established target of the PI3K/Akt signaling pathway [20] . Thus, inhibiting GSK3h -a negative regulator of cardiac hypertrophy, prevents the nuclear export of NFAT [19, 37] , which promotes hypertrophy. This scheme is consistent with a report by Antos et al. who showed that localization of NFATc1 to the nucleus in response to activated calcineurin was diminished in the presence of a GSK3h inhibitor [39] . Further, it was recently shown that an increase in PI3K activity can induce cardiac hypertrophy, whereas transgenic overexpression of a dominant -negative PI3K decreases cardiac mass [40] . Thus, by so doing, Fas-activated PI3K signaling can potentiate the Ca 2+ -activated calcineurin hypertrophic pathway by removing the inhibitory influence of GSK3h.
The involvement of TK phosphorylation in Fas-induced hypertrophy
In agreement with our previous work showing that TK inhibitors block the acute effects of Fas activation, genistein also prevented Fas-mediated hypertrophy. Since a discussion of the potential sites possibly affected by genistein has been presented recently [6] , this issue is addressed here only in brief. In principle, genistein can affect the hypertrophic pathway at 3 different sites: (1) The Fas receptor. Although the TK associated with Fas activation have not been fully characterized, they can be inhibited by genistein [41, 42] (2) PLC. A number of studies proposed a possible interaction between the TK Fyn and Lck, and PLC. Some studies claim to have identified specific phosphorylation sites on PLCg [43] , while others suggest that PLC activation is related to TK phosphorylation, by forming a stable complex between these two [44, 45] . (3) The 1,4,5-IP 3 receptor and the PI3K pathway. Gulbins et al. reported that PI3K, shown to be stimulated by Fas activation, [1] is dependent upon TK phosphorylation [46] . Furthermore, it was recently reported that PI3K might act as a regulator of [Ca 2+ ] i in cardiac cells [34] . PIP3 (a PI3K product synthesized from PIP2) anchors Tec -a tyrosine kinase and PLCg to the membrane, thus enabling 1,4,5-IP 3 production from PIP2 [34] . Accordingly, Jayaraman et al. showed that: (1) during T lymphocyte stimulation the IP 3 R is physically associated with Fyn, and (2) in Fyn knockout mice, IP 3 R phosphorylation was reduced [47] . Collectively, these and other studies support the notion that TK phosphorylation participates, probably at multiple sites, in the Fas signaling pathway leading to hypertrophy. 
